Episode Details

On our latest Small Cap Sunday podcast, we profile MindMed (NASDAQ: MDMD), an industry leader in the psychedelic space. We’ll review what the company accomplished in 2024, and what investors can anticipate hearing into 2p25. In 2024, MindMed made significant announcements, including the dosing of the first patient in their Phase 3 Voyage study of MM120 for Generalized Anxiety Disorder (GAD) on December 16. This study aims to assess the efficacy and safety of MM120 ODT versus placebo, involving around 200 participants in the U.S. MindMed's share price has fluctuated throughout the year. Starting at $3.30, it surged to $5.50 in May after positive Phase 2b trial results and FDA Breakthrough Therapy Designation. Despite a dip to $4.80 in August, it rebounded to $7.00 in December with the Phase 3 milestone. One of MindMed's strengths is their executive team, featuring Dr. Javier Muniz, who brings over 20 years of FDA experience. This expertise enhances their credibility and attractiveness for potential big pharma buyouts. Heading into 2025, MindMed will need to successfully complete Phase 3 trials and navigate the competitive psychedelic market. Investors should monitor their progress, share price, and strategic moves, as the company is well-positioned for potential buyout interest and could transform treatment for brain health disorders. #psychedelics #PsychedelicResearch #PsychedelicTherapy #PsychedelicCommunity #mentalhealth ⁠#anxiety #mentalhealthmatters ⁠#psychedelicstocks #bigpharma Want to watch more videos about Small Cap Stocks?    • What's Next for Psychedelic Stock Cyb...     • Bitcoin Surpasses $100K: Unprecedente...     • How Psychedelic Companies Attract Ana...   Want to be updated on Cannabis, Small Cap, AI, and Crypto? Subscribe to our Daily Baked in Newsletter! https://newsletter.thedalesreport.com... Find us as well on Facebook, Twitter, Instagram, LinkedIn and on the Web: Facebook:

Listen Now